In mature and immature teratoma the treatment is surgical. The risk of recu
rrence can be estimated from the parameters primary site (with the coccygea
l tumors being most at risk), histological grade of immaturity and complete
ness of the primary resection including the adjacent organ of origin (coccy
x, ovary, testis etc.). In case of a microscopically complete tumor resecti
on there is no role for adjuvant chemo- or radiotherapy irrespective of the
histological grade of immaturity.
Malignant germ-cell tumors (GCT) account for 2.9% of all malignant tumors o
f children younger than 15 years of age. More than half of the tumors occur
at extragonadal sites such as the ovaries (26%), the coccygeal region (24%
), the testes (18%) and the brain (18%) represent then primary sites.
In patients with extensive tumor growth, metastatic disease or secreting in
tracranial tumors a delayed tumor resection after preoperative chemotherapy
is preferable. In these patients malignant non-seminomatous GCT may be dia
gnosed clinically due to the increased serum or cerebrospinal fluid levels
of the tumor markers AFP and/or beta-HCG. Current risk adapted treatment pr
otocols containing cisplatinum allow long-term remissions in about 80% incl
uding patients with bulky or metastatic tumors. In the cisplatinum era the
prognostic factors like histology, primary site of the tumor and initial tu
mor stage have partly lost their former impressive significance in infants
and children. On the other hand the completeness of the primary tumor resec
tion according to oncological standards has been established as the most po
werful prognostic parameter superior to tumor marker levels or primary site
of the tumor.